TY - JOUR
T1 - The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain
AU - Sellinger-Barnette, Mary M.
AU - Mendels, J.
AU - Frazer, A.
N1 - Funding Information:
*This investigation was supported from the Veterans Administration 29094. t Preliminary reports of this work were presented at the 62nd and 63rd Annual Meetings of the Federation of American Societies for Experimental Biology, 1978 and 1979. 1 Supported by U.S. Public Health Service Training Grant 07302 and National Science Foundation predoctoral fellowship. The work presented here is in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pharmacology, University of Pennsylvania.
PY - 1980/5
Y1 - 1980/5
N2 - The effect of a variety of psychotropic drugs, given to rats repeatedly over 16 days, on the number of beta-adrenergic receptor binding sites in cerebral cortex was measured. Labelled dihydroalprenolol, [3H]-DHA, was used to measure beta-adrenergic binding sites. Both tricyclic antidepressants (amitriptyline, chlorimipramine, desmethylimipramine and nortriptyline) and monoamine oxidase inhibitors (nialamide and tranylcypromine) lowered [3H]-DHA binding significantly. Repeated treatment of rats with the antidepressant. iprindole. produced the same effect as did treatment with bupropion. However, the experimental antidepressant mianserin did not reduce [3H]-DHA binding nor did 11 other psychoactive compounds including chlorpromazine, diazepam, l-DOPA, tripelennamine and cocaine. The reduction in [3H]-DHA binding produced by nialamide or iprindole treatment was due to a reduction in the maximum number of beta-adrenergic receptor binding sites. Drug treatment-induced lowering of [3H]-DHA binding sites in cerebral cortex appears to have utility as a pre-clinical test for antidepressant drugs.
AB - The effect of a variety of psychotropic drugs, given to rats repeatedly over 16 days, on the number of beta-adrenergic receptor binding sites in cerebral cortex was measured. Labelled dihydroalprenolol, [3H]-DHA, was used to measure beta-adrenergic binding sites. Both tricyclic antidepressants (amitriptyline, chlorimipramine, desmethylimipramine and nortriptyline) and monoamine oxidase inhibitors (nialamide and tranylcypromine) lowered [3H]-DHA binding significantly. Repeated treatment of rats with the antidepressant. iprindole. produced the same effect as did treatment with bupropion. However, the experimental antidepressant mianserin did not reduce [3H]-DHA binding nor did 11 other psychoactive compounds including chlorpromazine, diazepam, l-DOPA, tripelennamine and cocaine. The reduction in [3H]-DHA binding produced by nialamide or iprindole treatment was due to a reduction in the maximum number of beta-adrenergic receptor binding sites. Drug treatment-induced lowering of [3H]-DHA binding sites in cerebral cortex appears to have utility as a pre-clinical test for antidepressant drugs.
UR - http://www.scopus.com/inward/record.url?scp=0018900302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018900302&partnerID=8YFLogxK
U2 - 10.1016/0028-3908(80)90052-0
DO - 10.1016/0028-3908(80)90052-0
M3 - Article
C2 - 6248811
AN - SCOPUS:0018900302
VL - 19
SP - 447
EP - 454
JO - Neuropharmacology
JF - Neuropharmacology
SN - 0028-3908
IS - 5
ER -